Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Trial Profile

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Crisantaspase (Primary) ; Cytarabine; Fludarabine
  • Indications Haematological malignancies
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2021.
    • 20 Sep 2017 Planned initiation date changed from 1 Dec 2016 to 1 Feb 2018.
    • 19 Sep 2016 Planned primary completion date changed from 1 Jul 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top